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Protocol Article
A protocol for metabolic characterization of
human induced pluripotent stem cell-derived
cardiomyocytes (iPS-CM)
Alisha House, Erica Fatica, Rohan Shah, Jared Stergar,
Ryan Pearce, Yana Sandlers*
Department of Chemistry, Cleveland State University, Cleveland, OH 44115, United States
A B S T R A C T
Recent advances in human induced pluripotent stem cell-derived cardiomyocytes (iPSCM) field offer a novel
platform for modeling cardiac metabolism, heart diseases drug candidates screening and cardiac toxicity
assessments. These workflows require a fully functional characterization of iPSCMs. Here we report a step by step
protocol for iPSCM metabolic characterization. The described assays cover analysis of small metabolites involved
in a vital metabolic pathways.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Specifications Table
Subject Area: Biochemistry, Genetics and Molecular Biology
More specific subject
area:
Metabolic profiling
Protocol name: IPS-CM functional characterization
Reagents/tools: Included in each section of the protocol
Experimental design: Functional and beating induced pluripotent stem cells derived cardiomyocytes are cultured in a standard
conditions or in the presence of 13C labeled glucose. Cells are harvested through the developed protocol,
followed by mass spectrometry assays to analyze small metabolites, glucose uptake and lactate/pyruvate
production.
Trial registration: N/A
Ethics: N/A
Value of the Protocol
 new metabolic assays expand iPSCM functional analysis beyond already established techniques
 assays can be applied to compare profiles, glucose uptake and lactate/pyruvate production in wild type vs. mutant cells
 assays can be applied to monitor vital metabolites alterations during therapeutic interventions
Description of protocol
The discovery of cell reprogramming methods to obtain human induced pluripotent stem cells
(iPSc) from adult somatic cells, followed by differentiation to cardiomyocytes, provides a unique
opportunity to generate an unlimited number of induced pluripotent derives cardiomyocytes
(iPS-CM) carrying specific cardiac genotypes and phenotypes. This invaluable model is an innovative
tool for creating in vitro cardiac cellular models that can be utilized for new therapeutic assessments,
screening of drug’s induced cardiac toxic effects and a discovery of as-yet unknown metabolic
mechanisms that underlie cardiac manifestation of the inherited heart diseases. The ability to
successfully translate cell-based studies into a clinical studies requires efficient tools for functional
characterization of iPSC-CM. For this purpose electrophysiological and imaging techniques are
utilized. These methods allow to monitor ion channel activities [1], measure action potentials, changes
in Ca+2 fluxes [2], mitochondria viability and apoptosis [3]. Here we report new metabolic assays that
allow to expand functional analysis beyond already established techniques and provide metabolic
characteristics of iPSCM for the purpose of disease modeling, drug candidates screening and
therapeutic agents cardiac safety assessments.
Method details
Differentiation
iPSC cells were kindly contributed by Duke University core facility. Differentiation to
cardiomyocytes was induced by the modified small molecules protocol [4] (Fig. 1). Briefly hiPSCs
(passage >20) were passed at a 1:12 ratio and cultured on matrigel with Essential 8 Flex medium
(Thermo Fisher Scientific) until~100% confluency. At Day 0, prior to medium change, E8 media was
aspirated from cells, and they were washed with D-PBS. 1 mL of 0.5 mM EDTA in DPBS was added to
each culture well. Plates were placed in incubator for approximately 35 s. Upon removal from
incubator, dishes were gently tapped to dislodge only a small amount of cells. EDTA solution was
aspirated, and differentiation medium was added directly to the EDTA-treated cells. The medium was
changed to RPMI 1640 with B27 minus insulin supplement (A1895601, Life Technologies) with 6 mM
CHIR99021,10 ng/mL Activin A, and 50 ug/mL ascorbic acid. On day 1, medium was changed to RPMI
1640 with B27 minus insulin supplement (referred to as basal differentiation supplement). On day 2,
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medium was changed to basal differentiation supplement and 10 mM IWR-1. On day 4, medium was
refreshed with basal supplement and 10 mM IWR-1. Medium was changed on Day 6 to basal
differentiation supplement (without IWR-1). On Day 8, and every other day thereafter, medium was
refreshed with RPMI 1640 with B27 supplement (referred to as cardiomyocyte maintenance media).
Spontaneously contracting cardiomyocytes (Fig. 2, Supplemental video) were first observed on day 9.
Approximately 2 days after observing initial cardiomyocyte contractions, medium was changed to
RPMI 1640 with no glucose and supplemented with 4 mM lactate. Medium was changed 72 h later to
cardiomyocyte maintenance media.
Fig. 1. Differentiation protocol.
Fig. 2. Immunostaining analysis for cardiac specific markers 42 days post differentiation. (A) Cardiac troponin I (green) and
iroquois-class homeodomain protein (IRX4, red) and (B) α-actinin. Nuclei are shown by DAPI (blue).
A. House et al. / MethodsX 7 (2020) xxx–xxx 3
iPSCM harvest and extraction
All protocols below are adjusted for 1 well of a 6-well culture plate.
Materials
Labeled amino acids mixture, (Cambridge isotopes laboratories cat.no NSK-A)
Labeled acylcarnitines mixture, (Cambridge isotopes laboratories, cat.no NSK-B)
Tricarballylic acid (Sigma-Aldrich cat.no T53503) prepare 1 mM in water
Acetonitrile (VWR, cat.no BDH83640.100E LC/MS grade)
Chloroform (VWR, cat.no BDH83627 HPLC grade)
Water (VWR, cat.no BDH23595.100E HPLC grade)
Phosphate Buffered Saline (PBS), (VWR, cat.no 97063-658)
Metabolism quenching protocol
1. Aspirate culture media from iPSCM.
2. Wash cells twice with 1 mL cold PBS and one time with water. Ensure that water remains on cells
for no more than 30 s.
3. Add 1 mL cold acetonitrile and incubate cells in 20 C for 20 min. At the end of the 20 min period
white protein precipitate will appear on culture dish bottom.
4. Add 0.75 mL of cold water and with the plastic scraper, scrape cells from the bottom of the culture
dish.
5. Using a P1000 pipette, remove cell lysate to a 10 mL centrifuge tube.
6. Repeat steps 3–5 one more time. To ensures complete recovery of lysate it is recommended to use
same cells scraper and pipette tip.
7. Add internal standard. Internal standards preparation and amounts varies with the analysis type.
See notes #1-3.
8. To the collected cell lysate (step#4), add 1 mL of cold chloroform.
9. Vortex sample and centrifuge at 5000 rpm for 15 min. After completion of the centrifugation step,
a clear separation will be observed between the polar (upper) phase, non-polar (lower) phase, and
the inter-phase pellet that contains proteins and DNA.
10. From the upper polar phase, take an aliquot of 250 mL for acylcarnitines and amino acids assay and
transfer to the clean tube. Label " amino acids and acylcarnitines".
11. Carefully remove and combine the rest of the upper polar phase with the bottom non-polar phase
in a clean tube. Label "small cellular metabolites by GC/MS".
12. Add 50 mL methanol to the remaining protein pellet and evaporate solvent under nitrogen stream
in room temperature.
13. Reconstitute protein with buffer and perform protein analysis by protein assay such as Bradford or
bicinchoninic acid (BCA).
Note #1- Preparation of working solution NSK-A. Internal standard vial contains labeled standards
for amino acids. For the stock solution, reconstitute dry powder in vial with 2 mL of water:methanol
(1:1 v%/v%). Complete reconstitution of the contents of one vial in 2 mL produce stock solution of
following metabolites. Alanine (2,3,3,3-2H4) 250 nmol/mL, L-Phenylalanine (ring-13C6) 250 nmol/mL,
L-Leucine (5,5,5-2H3) 250 nmol/mL, L-Valine (2H8) 250 nmol/mL, L-Arginine: HCl (5-13C; 4,4,5,5-2H4)
250 nmol/L, L-Citrulline (5,5-2H2) 250 nmol/mL, L-Tyrosine (ring-13C6) 250 nmol/mL, L-Ornithine: HCl
(5,5-2H2) 250 nmol/mL, L-Methionine (methyl-2H3) 250 nmol/mL, DL-Glutamic Acid (2,4,4-2H3)
250 nmol/mL, L-Aspartic Acid (2,3,3-2H3) 250 nmol/mL, Glycine (2-13C; 15N) 500 nmol/mL. For the
working solution-dilute stock solution 1:10 in methanol. Add 50 mL of the working solution to the cell
lysate.
Note #2- Preparation of working solution NSK-B. Internal standard vial contains labeled
acylcarnitines standards. For the stock solution, reconstitute dry powder in vial with 2 mL of
methanol. Complete reconstitution of the contents of one vial in 2 mL produce stock solution
of following metabolites: Free carnitine (76 nmol/mL), 2H3-Acetylcarnitine (19 nmol/mL),
2H3-Propionylcarnitine (3.8 nmol/mL), 2H3-Butyrylcarnitine (3.8 nmol/mL), 2H9-Isovalerylcarnitine
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(3.8 nmol/mL), 2H3-Octanoylcarnitine (3.8 nmol/mL), 2H9-Myristoylcarnitine (3.8 nmol/mL), 2H3-
Palmitoylcarnitine (7.6 nmol/mL). For the working solution-dilute stock solution 1:106 in methanol.
Add 100 mL of the working solution to the cell lysate.
Note#3- For the GCMS metabolic profile, add 25 mL of 1 mM tricarballylic acid
Acylcarnitines and amino acids assay
Materials
3N HCl n-Butanol (Sigma-Aldrich, cat.no 87472)
Prepare mobile phase A for chromatographic separation: 20% Water (0.1% Formic acid): 80%
Acetonitrile (0.1% Formic acid)
LC inline filter (VWR cat.no 97013-134)
Protocol
1. Dry 250 mL aliquots of the polar phase collected at step #10 and labeled "" amino acids and
acylcarnitines" with internal standards (note #1 and #2).
2. To the dried sample add 60 mL HCl-n-Butanol, cap tubes and incubate at 65 C for 30 min.
3. Cool to the room temperature and dry again.
4. Reconstitute with 100 mL of mobile phase A and transfer to vials for the analysis.
HPLC parameters
Introduce derivatized samples directly by the injection to the mass spectrometer instrument
through the inline filter with no chromatographic separation. Keep inline filter in HPLC oven at 32 C.
Inject 7 mL of a sample into a flowing solvent at 50 mL/min flow rate for the total 1.8 run time. Use only
mobile phase A isocratically.
MS/MS-tandem mass spectrometer
Use following tandem mass spectrometry scans for the high throughput: for the acylcarnitines
precursor ion scan at m/z 85 (Table 1, only saturated C2-18 acylcarnitines are included), for amino acids
neutral loss (NL 102, NL 119), and single reaction monitoring SRM m/z 231.1-m/z 70.1 for arginine
(Table 2).
Data analysis
Perform data analysis by Chemoview 2.2 software (SCIEX) or comparable software. Calculate peak
areas at 50% peak height.
Table 1
Saturated acylcarnitines by acyl chain length as butyl esters and their molecular ions.
Chain length [M+H]+/[M+H]+ Internal standard as butylesters
C2 260/263
C3 274/277
C4 288/299
C5 302/311
C6 316
C8 344/347
C10 372
C12 400
C14 428/437
C16 456/459
C18 484
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Representative data
See Figs. 3 and 4.
Fig. 3. Amino acids analysis: representative m/z profile of NL 102 scan (1) alanine, (2) alanine ISTD, (3) aspartic acid, (4) aspartic
acid ISTD, (5) glutamic acid (6) glutamic acid ISTD, (7) leucine/isoleucine, (8) leucine/isoleucine, (9) methionine, (10)
methionine ISTD, (11) ornithine, (12) ornithine ISTD, (13) phenylalanine, (14) phenylalanine ISTD, (15) tyrosine, (16) tyrosine
ISTD, (17) valine, (17) valine ISTD.
Fig. 4. Acylcarnitines assay : represantative precursor ion scan (m/z 85) profile. (1) Free carnitine (C0), (2) C0 ISTD, (3) C2, (4) C2
ISTD, (5) C3, (6) C3 ISTD, (7)C4, (8)C4 ISTD, (9) C5, (10) C5 ISTD, (11) C8, (12) C8 ISTD, (13) C14, (14)C14 ISTD, (15) C16, (16) C16 ISTD,
(17) C18.
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Small cellular metabolites by GC/MS profiling
Materials
Anhydrous pyridine (Sigma-Aldrich cat.no 270970)
Metoxyamine hydrochloride (Sigma-Aldrich cat.no 226904) prepare 20 mg/mL in anhydrous
pyridine
N,O-Bis(trimethylsilyl)trifluoroacetamide/BSTFA (Sigma-Aldrich cat.no B-023)
Derivatization protocol
1. Dry combined polar and non-phases collected at step #11 /metabolism quenching and labeled as "
small cellular metabolites by GC/MS".
2. Add 40 mL methoxyamine hydrochloride in pyridine (20 mg/mL).Cap tubes, vortex and incubate at
80 C for 1 h.
3. Cool to the room temperature and add 60 mL N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA).
Cap tubes, vortex and incubate at 70 C for 30 min.
4. Cool to the room temperature and transfer to vials for GCMS analysis.
GCMS parameters
GCMS
Ion Source EI (Electron Ionization)
Source Temperature 280 C
Quad Temperature 150 C
Fixed Electron Energy 70eV
Acquisition Type Scan
Injection Volume 1 uL
Solvent Delay 6 min
Column HP-5MS 5% Phenyl Methyl Silox (30 m  250 um  0.25um)
Mode Splitless
Time Program
Initial Setpoint 80 C (hold 3 min)
Ramp 15 C/min
Hold 305 C (3 min)
Table 2
Amino acids as butyl esters and their molecular ions. Additional amino acids can be detected and quantified with the matching
stable-isotopic labeled standards.
Target amino acid [M+H]+/[M+H]+ Internal standard as butylesters
Alanine 146/150
Arginine 231/236
Aspartic Acid 246/249
Citrulline 232/234
Glutamic acid 260/263
Glycine 132/134
Leucine/Isoleucine 188/191
Methionine 206/209
Ornithine 189/191
Phenylalanine 222/228
Tyrosine 238/244
Valine 174/182
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Data analysis. Mass spectra analyzed by freely available AMDIS software and Fiehn library (Agilent).
Identified metabolites are shown in Fig. 5. Normalize metabolite's levels to the reference standard
tricarballylic acid m/z 377 (as BSTFA derivative) as following: use mass spectra to calculate the ratio of
peak areas of target metabolites to the reference internal standard (tricarballylic acid) and to the total
protein amount of each cell pellet as determined by the Bradford assay.
Relative level ¼
Peak area of metabolite= Peak area of reference standardð Þ½ 
reference standard in nmol½  units
Protein amount
Representative data
Glucose uptake, lactate and pyruvate production analysis
Glucose and lactate represent a major carbon sources for the myocardial energy metabolism.
Whereas pyruvate is produced from lactate through the reaction catalyzed by lactate dehydroge-
nase, lactate to pyruvate ratio is a good surrogate for cytosolic redox state and correlates well with
NAD+/NADH ratio.
For glucose uptake and lactate/pyruvate production assays incubate cells with 13C labeled glucose.
We recommend to use a fully labeled commercial available 13C6 glucose.13C labeled glucose
concentration in the cell media can be ranged from low (5 mM) to high (25 mM) concentration.
Glucose uptake is measured by monitoring decrease in 13C6 Glucose concentration in culture media
over the time (Fig. 8) and lactate and pyruvate production by the appearance of 13C3 labeled lactate
(Fig. 8) and 13C3
Materials
13C6 labeled glucose (Sigma-Aldrich, cat.no 389374)
1 mM galactose (Sigma-Aldrich, cat.no PHR1206)
Tricarballylic acid (Sigma-Aldrich cat.no T53503) prepare 1 mM in water
Acetic anhydride (Sigma-Aldrich, cat.no 242845-5G)
Fig. 5. (1) Lactate, (2) Glycolic acid, (3) valine, (4) alanine, (5) leucine, (6)3-hydroxybutyric acid, (7)proline, (8) isoleucine, (9)
serine, (10) octanoic acid, (11) glycine, (12)succinate, (13) fumarate, (14) threonine, (15) methionine, (16) aspartic acid, (17)
malate, (18) glutamic acid, (19) glycerol-1-phosphate, (20) ornithine, (21) isocitrate (22) citrate, (23) tyrosine, (24) lysine, (25)
ascorbic acid, (26) palmitoleic acid (27) palmitic acid, (28) inositol, (29) linoleic acid (30) oleic acid, (31) stearic acid, (32)
cholesterol.
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Hydroxylamine hydrochloride (Sigma-Aldrich cat.no HX0770) prepare 0.2 M in anhydrous
pyridine
Metoxyamine hydrochloride (Sigma-Aldrich cat.no 226904) prepare 20 mg/mL in anhydrous
pyridine
N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-Butyldimethylchlorosilane/
MTBSTFA (Sigma-Aldrich cat.no 375934)
Methanol (Sigma-Aldrich, cat.no 34860-1L-R)
Chloroform (Sigma-Aldrich, cat.no CX1050-1)
Protocol
1. Grow cells under standard culture conditions. To begin experiment with 13C6 glucose, aspirate
media and wash cells twice with 1x D-PBS.
2. Add 2 mL of RPMI 1640 (no glucose) media supplemented with 5 mM–25 mM 13C6 labeled glucose.
3. In the course of the experiment, remove aliquots of cell media at 0, 30, 60, 120, and 240 min. Note-
use more media initially if you plan to perform experiment for more than six hours.
Derivatization for GCMS analysis for the glucose uptake
1. To the 75 mL of the collected cell media aliquots add 25 mL of 1 mM galactose solution (used as
internal standard) and 400 mL of methanol followed by 400 mL of chloroform.
2. Vortex samples and centrifuge at 5000 rpm for 8 min. Transfer upper polar phase to the new tube
and dry under nitrogen at room temperature.
3. Add 100 mL of 0.2 M hydroxylamine hydrochloride in pyridine, cap tubes and incubate at 90 C for
40 min.
4. Cool to the room temperature and then add 100 mL of acetic anhydride followed by incubation at
90 C for 60 min.
5. Dry down derivatized samples by nitrogen stream in room temperature and re-suspend in 100 mL
of ethyl acetate.
GCMS parameters. Following ions were monitored: m/z 319 for glucose, and m/z 314 for galactose.
GCMS
Ion Source EI (Electron Ionization)
Source Temperature 280 C
Acquisition Type SIM
Injection Volume 1 uL
Solvent Delay 6 min
Column HP-5MS 5% Phenyl Methyl Silox (30 m  250 mm  0.25 mm)
Mode Splitless
Time Program
Initial set point 80 C (hold 3 min)
Ramp 15 C/min up to 180 C
Ramp 5 C/min up to 205 C
Ramp 1 C/min up to 212 C
Ramp 15 C/min up to 310 C min
Hold 310 C (5 min)
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Representative chromatogram
Derivatization protocol for the lactate and pyruvateproduction assay
1. To the 75 mL of the collected cell media aliquots (Step #3) add 25 mL of 1 mM tricarballylic acid and
dry samples.
2. Add 40 mL methoxyamine hydrochloride in pyridine (20 mg/mL), vortex and incubate at 80 C
for 1 h.
3. Cool to room temperature and add 60 mL MTBSTFA. Cap tubes, vortex and heat at 70 C for 30 min.
4. Cool to the room temperature and transfer to GCMS vials.
GCMS parameters
Following ions were monitored: for 13C3 lactate m/z 264, for 13C3 pyruvate m/z 177 and m/z 377 for
tricarballylic acid.
Data analysis
Note: Data analysis was performed under validated assumption that there is no significant natural
abundance contribution to the 13C3-Lactate and 13C3pyruvate, thus for the concentration calculations
the data was not corrected for 13C natural abundance.
Relative level ¼
½Peak area of 13C3l lactate=ðPeak area of referencestandardÞ
reference standard in ½nmol units
Protein amount
Relative level ¼
½Peak area of 13C3pyruvate=ðPeak area of reference standardÞ
reference standard in ½nmol units
Protein amount
Fig. 6. Representative GCMS chromatogram. Cell media extract 13C6 Glucose and galactose as internal standard.
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Representative chromatogram
See Fig. 7.
Results and discussion
In recent years there are emerging evidence for studies involved human iPSCM in basic science,
regenerative medicine, and the pharmaceutical industry. Although much progress has been made in
the genetic and electrophysiological characterization of iPSCMs, it is not understood well how
Fig. 7. Representative GCMS chromatogram. Cell media analysis for pyruvate and lactate.
Fig. 8. Representative 13C6 glucose uptake and 13C3 lactate production for iPSCM.
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metabolic phenotypes are affected in the course of the disease or in response to newly developed
therapies. Thus, to fulfill the potential for iPSCM related studies, there is a need for metabolic assays
complementary to the existing functional characterization methods. Here, we developed mass
spectrometry-based quantitative assays and applied them for metabolic characterization of iPS-CM.
Using these assays we successfully profiled a variety of small metabolites involved in different
biochemical pathways.
Acylcarnitines have a central role in the transport of fatty acids into the mitochondria for
subsequent β-oxidation. Acylcarnitine analysis can be especially useful for iPSCM models of heart
failure [5,6], diabetic cardiomyopathy [7] and fatty acid oxidation disorders (FAOD) with cardiac
manifestation [8,9]. Given the fact that the relative acylcarnitines pools and individual contributions
within the total carnitine pool are closely correlated to the intra-mitochondrial acyl-CoA pools it is
suggested that proposed assay is a powerful tool for the mitochondrial dysfunction investigations in
iPSCM. Amino acids also have a high significance to heart metabolism. Although under physiological
condition, the human heart has minimal reliance on amino acids for ATP, some amino acids replenish
citric acid cycle and their utilization increases during heart failure, hypoxia or another pathological
metabolic remodeling. The proposed high throughput assay analyses acylcarnitines and amino acids
in two minutes and has an automated data analysis algorithm (Chemoview/ABSCIEX) but can be also
performed manually.
GCMS metabolic profiling
The proposed gas chromatography-mass spectrometry metabolic profiling allows semiquantita-
tive analysis of small metabolites (50–650 Da). Although method requires extensive sample
preparation including chemical derivatization [10] to increase metabolites' volatility for gas
chromatography, it was able to detect thirty two metabolites extracted from one well (standard
six well plates, 1.2–1.5 * 106 iPS-CM per well in average). For metabolites identification we applied
freely available deconvolution software AMDIS [11] and commercially available spectral library [12].
Under standardized EI-GCMS conditions, every metabolite produced unique fragmentation pattern
that was matched to the library based on >78% match criteria. The identified small metabolites
included amino acids, carbohydrates, fatty acids, and sterols.
Lactate/pyruvate assay
Pyruvate is the end product of glycolysis and it also can be produced from lactate through the
reaction catalyzed by lactate dehydrogenase. Thus, lactate to pyruvate ratio is a good surrogate for
cytosolic redox state and correlates well with NAD+/NADH ratio. Dysfunctions in a citric acid cycle or
respiratory chain may lead to reduced pyruvate oxidation and to the abnormal lactate to pyruvate
ratios. At the same time, excessive lactate production is an indication of lactic acidosis which is
detrimental to the iPSCM contractility.
Glucose uptake assay
In iPSCM cellular system, glucose is a primary energy source, thus uptake assay is an important
tool. Alterations in glucose uptake can reflect overall metabolic changes, and in conjunction with the
pyruvate production can indicate glycolysis flux changes. At the same time, glucose uptake monitoring
can be indicative of the over or down expression of glucose transporters.
Conclusion
We have developed a workflow for the analysis of small metabolites in iPSCM involved in energy-
related pathways. The workflow combines GCMS and LC–MS/MS platforms serves as an important tool
for iPSCM metabolic characterization and can provide complementary metabolic endpoints to
monitor therapeutic interventions. Future studies to expand iPSCM metabolic profiles are warranted.
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